What is Cardarine? A Comprehensive GW501516 Review

Buy GW501516 (Cardarine)

GW-501516, also known as Cardarine, was first created in the mid-1990s by pharmaceutical companies Glaxo Smith Kline and Ligand Pharmaceuticals to help treat metabolic and cardiovascular diseases. Drug development was abandoned in 2007, and GW501516 use started to become popular among athletes, fitness enthusiasts, and bodybuilders. Performance enhancement from Cardarine was of main interest. A summary of Cardarine benefits include increased endurance, increased fat utilization, improved HDL (high density lipoprotein) levels, and decrease LDL (low density lipoprotein levels).  

Cardarine (GW501516) is not a SARM (selective androgen receptor modulator), although it is often falsely categorized as one. Cardarine is a selective agonist (activator) of the PPARδ receptor with a 24 hour half life. Research has shown GWW501516 doses of 10-20mg per day to be most effective.

In this Cardarine review, we are going to talk more about how Cardarine increase endurance, improved physical performance, fat loss, and improvements in metabolic parameters.

GW501516 vs. DMSO Control

Increased Endurance:

By Activating the PPARδ receptor, Cardarine (GW501516) alters specific gene expression, causing a change in energy utilization in the body. This is the main mechanism of action whereby Cardarine results in increased physical and cardiovascular performance and endurance. In fact, many Olympic athletes were found to have taken advantage of Cardarine performance enhancement benefits during the 2008 Olympic Games.

Fat Loss:

Cardarine (GW501516) changes the way the body utilizes energy (fatty acids and glucose). The increased fatty acid utilization caused by Cardarine can aid in the loss of body fat and improve the ratio of lean muscle to body fat. Many GW501516 reviews have suggested that this effect on fat loss is noticed by many. Cardarine has also been shown to help optimize insulin sensitivity, which can further aid in improved body composition. Interestingly, research has shown that fat loss occurs with GW501516 with or without changes in diet.

Metabolic Parameters:

In this GW501516 review, we have discussed many ways in which Cardarine can enhance performance and fat loss. However, many Cardarine reviews show interest in Cardarine benefits just for metabolic health. Improved insulin sensitivity is a great benefit for optimizing metabolic health.

Where to Buy Cardarine (GW501516)?

Cardarine (GW501516) is available from ELV Bioscience for research or laboratory use. Our research chemicals are made in an ISO9001 cGMP facility within the United States under strict purity, potency, and quality control standards.

Buy GW501516 (Cardarine) Online


Sahebkar A, Chew GT, Watts GF (2014). “New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease”. Expert Opin Pharmacother. 15 (4): 493–503. doi:10.1517/14656566.2014.876992. PMID 24428677. “Despite these promising early results, the further investigation and development of GW501516 was discontinued after observations in animal studies of its association with the rapid induction of cancers in several organs (liver, stomach, tongue, skin, bladder, ovaries, womb and testes”

“Anti-doping agency warns cheats on the health risks of Endurobol”. The Conversation. 2013-03-22.

Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM (April 2001). “A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport”. Proc. Natl. Acad. Sci. U.S.A. 98 (9): 5306–11. doi:10.1073/pnas.091021198. PMC 33205. PMID 11309497.

Uwe Dressel; Tamara L. Allen; Jyotsna B. Pippal; Paul R. Rohde; Patrick Lau & George E. O. Musc (2003). “The Peroxisome Proliferator-Activated Receptor β/δ Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells”. Molecular Endocrinology. 17 (12): 2477–93. doi:10.1210/me.2003-0151. PMID 14525954.

Barish GD, Narkar VA, Evans RM (March 2006). “PPAR delta: a dagger in the heart of the metabolic syndrome”. J. Clin. Invest. 116 (3): 590–7. doi:10.1172/JCI27955. PMC 1386117. PMID 16511591.

Wolf G (November 2003). “The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis”. Nutr. Rev. 61 (11): 387–90. doi:10.1301/nr.2003.nov.387-390. PMID 14677574.

Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ (2009). PS 895 – Rat carcinogenicity study with GW501516, a PPAR delta agonist (PDF). 48th Annual Meeting of the Society of Toxicology. Baltimore: Society of Toxicology. p. 105. Archived from the original (PDF) on 2015-05-04.

Billin AN (October 2008). “PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home”. Expert Opin Investig Drugs. 17 (10): 1465–71. doi:10.1517/13543784.17.10.1465. PMID 18808307.

“WADA issues alert on GW501516”. World Anti-Doping Agency. 2013-03-21. Archived from the original on June 2, 2013.

Thevis M, Geyer H, Thomas A, Schänzer W (May 2011). “Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet”. Drug Test Anal. 3 (5): 331–6. doi:10.1002/dta.283. PMID 21538997.

Newsholme SJ, Dunsford WS, Brodie T, Brennan C, Brown M, Geiger LE (2009). PS 896 – Mouse carcinogenicity study with GW501516, a PPAR delta agonist (PDF). 48th Annual Meeting of the Society of Toxicology. Baltimore: Society of Toxicology. p. 105. Archived from the original (PDF) on 2015-05-04.

Sprecher DL (December 2007). “Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta”. Am. J. Cardiol. 100 (11 A): n20–4. doi:10.1016/j.amjcard.2007.08.009. PMID 18047848.

Sanchis-Gomar F, Lippi G (March 2012). “Telmisartan as metabolic modulator: a new perspective in sports doping?”. J Strength Cond Res. 26 (3): 608–10. doi:10.1519/JSC.0b013e31824301b6. PMID 22130396.